09/06/21 -"With COVID-19 vaccine programmes fast gaining pace, a gradual recovery is expected in the Anti-Histamine markets heading into H2 21, indicating increasing demand for the high-margin drug, Bilastine. ..."
Pages
49
Language
English
Published on
09/06/21
You may also be interested by these reports :
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...
24/09/25
When we last pushed the Spanish blood plasma giant Grifols’ (BUY ; Spain) investment case in May 2024, investor confidence was close to its nadir, as ...